(R)-Apremilast(CAS: 608141-44-2)

(R)-Apremilast (CAS: 608141-44-2) is subject to regulatory guidelines under the Globally Harmonized System (GHS) for classification and labeling of chemicals, including hazards related to skin and eye irritation. In the European Union, it falls under the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) regulation. Additionally, the U.S. Food and Drug Administration (FDA) and Environmental Protection Agency (EPA) have specific requirements for its handling and reporting.

In the synthesis of (R)-Apremilast (CAS: 608141-44-2), chemists may explore using enantiopure or racemic precursors. Common alternatives include the use of chiral pool compounds or asymmetric synthesis methodologies. Additionally, synthetic routes may involve using achiral reagents and employing chiral auxiliary strategies for enantioselective synthesis.

The market for (R)-Apremilast (CAS: 608141-44-2) is driven by its use as a therapeutic agent for treating psoriasis and other inflammatory conditions. Research trends focus on understanding its mechanisms of action, developing new formulations, and exploring its potential in other therapeutic areas. Market analysis indicates growing demand, particularly in the pharmaceutical industry, with ongoing clinical trials and regulatory approvals driving industry growth.

Waste containing (R)-Apremilast (CAS: 608141-44-2) should be collected in a manner that minimizes environmental exposure. Proper waste management includes using appropriate containers and labeling them as hazardous. For disposal, it is recommended to use professional waste disposal services that comply with local and national regulations. Environmental protection precautions, such as ensuring the waste is not released into water bodies, should be taken during collection and disposal processes.